Cited 4 times in
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.